Bogusław Maciejewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bogusław Maciejewski has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Rafal Tarnawski
PGOG, Warsaw, Poland; Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland
2 shared publications - Wojciech Majewski
Radiotherapy Department, Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO), 44-102 Gliwice, Poland
2 shared publications - Adam Bekman
Medical Physics Department, Maria Sklodowska-Curie National Research Institute of Oncology, Branch Gliwice, Gliwice, Poland
1 shared publication - Adam Idasiak
II Radiotherapy and Chemotherapy Clinic and Teaching Hospital, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland
1 shared publication - Agnieszka Czarniecka
3rd Department of Oncological Surgery M. Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
1 shared publication - Aleksandra Napieralska
Department of Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Branch Gliwice, Gliwice
1 shared publication
Latest Publications
- Open Access
- 8 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Long term effectiveness of intraoperative radiotherapy given as a boost in adjuvant treatment for oral cavity cancers
The oral cancer treatment of choice is surgical excision with an organ preservation, if it is possible. Radiation therapy is commonly used as a postoperative treatment. Delivering radiation dose during surgery, defined as intraoperative radiotherapy (IORT), can be very useful especially in case of high risk of recurrence or where gross or macroscopic residual disease are present. The aim of this retrospective study is to evaluate the effectiveness of IORT combined with postoperative fractionated irradiation (EBRT) of patients with squamous cell carcinoma of the oral cavity. The study included 23 patients: IORT dose of 5–7.5 Gy was delivered using 50 kV X-rays generated by INTRABEAM™, combined with EBRT of 50–60 Gy in 25–30 fractions depending on presence of extracapsular invasion and narrow or positive surgical margins. Standard statistical tests were used. Median follow up was 64 months (range 8–222 months). The 5-year local tumour control was 92% and 82.5% in the 10-year follow-up. The 5-year overall survival (OS) was 56% and decreased to 45% during the next 5 years. There were no differences in the LTC, DFS and OS regarding sex, T-stage, grade and tumour localization, although a small group of analysed cases may raise some uncertainties. Acute side effects of combined IORT and EBRT were mild and no late complications occurred. The present study indicated that low-energy X-rays IORT combined with postoperative EBRT is a feasible and safe therapeutic modality which likely reduces a risk of locoregional recurrences.
- 8 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Open AccessLong term effectiveness of intraoperative radiotherapy given as a boost in adjuvant treatment for oral cavity cancers
The oral cancer treatment of choice is surgical excision with an organ preservation, if it is possible. Radiation therapy is commonly used as a postoperative treatment. Delivering radiation dose during surgery, defined as intraoperative radiotherapy (IORT), can be very useful especially in case of high risk of recurrence or where gross or macroscopic residual disease are present. The aim of this retrospective study is to evaluate the effectiveness of IORT combined with postoperative fractionated irradiation (EBRT) of patients with squamous cell carcinoma of the oral cavity. The study included 23 patients: IORT dose of 5–7.5 Gy was delivered using 50 kV X-rays generated by INTRABEAM™, combined with EBRT of 50–60 Gy in 25–30 fractions depending on presence of extracapsular invasion and narrow or positive surgical margins. Standard statistical tests were used. Median follow up was 64 months (range 8–222 months). The 5-year local tumour control was 92% and 82.5% in the 10-year follow-up. The 5-year overall survival (OS) was 56% and decreased to 45% during the next 5 years. There were no differences in the LTC, DFS and OS regarding sex, T-stage, grade and tumour localization, although a small group of analysed cases may raise some uncertainties. Acute side effects of combined IORT and EBRT were mild and no late complications occurred. The present study indicated that low-energy X-rays IORT combined with postoperative EBRT is a feasible and safe therapeutic modality which likely reduces a risk of locoregional recurrences.
- 1 January 2001
- Published by S. Karger AG
- Vol. 37, 174-184
How the Game Is Played - Challenge between Therapeutic Benefit and Acute Toxicity in Fractionated Radiotherapy
- 1 January 2001
- Published by S. Karger AG
- Vol. 37, 174-184
How the Game Is Played - Challenge between Therapeutic Benefit and Acute Toxicity in Fractionated Radiotherapy